3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
Ismail M. Meraz(The University of Texas MD Anderson Cancer Center), Jack A. Roth(The University of Texas MD Anderson Cancer Center), Mourad Majidi(The University of Texas MD Anderson Cancer Center), Qi Wang(Tongji University), Yonathan Lissanu(The University of Texas MD Anderson Cancer Center), Bingliang Fang(The University of Texas MD Anderson Cancer Center), Min Jin Ha(University of North Carolina at Chapel Hill), Sung Yun Jung(Baylor College of Medicine), Franziska Haderk(Boehringer Ingelheim (Germany)), Ruping Shao(The University of Texas MD Anderson Cancer Center), Victor Olivas(University of California, San Francisco), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Jonathan W. Riess(University of California Davis Medical Center), Jing Wang(The University of Texas MD Anderson Cancer Center), Feng Li(The University of Texas MD Anderson Cancer Center), Huiqin Chen(Soochow University), Lihui Gao(China University of Mining and Technology), Renduo Song(The University of Texas MD Anderson Cancer Center), Philippe Gui(University of California, San Francisco), Feng Meng(The University of Texas MD Anderson Cancer Center), Trever G. Bivona(University of California, San Francisco)
Cited by 11
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k